The University of Kansas Cancer Center

https://www.kucancercenter.org/

 

The Use of IO Agents in Metastatic NSCLC: Overview of Anti-PD-1/Anti-PD-L1 Agents and Their Combinations, and Outcomes of Pivotal Trials

846 views
November 12, 2019
Comments 0
Login to view comments. Click here to Login